Arsenic trioxide induces cervical cancer apoptosis, but specifically targets human papillomavirus-infected cell populations

Anti-Cancer Drugs

Volumn 23, Issue 3, 2012, Pages 280-287

  Wen, Xuesong ^a,c   Li, Dong ^a,c   Zhang, Yunyan ^c   Liu, Shiping ^c   Ghali, Lucy ^a   Iles, Ray K ^a,b  

^a MIDDLESEX UNIVERSITY   (United Kingdom)

^b ANGLIA RUSKIN UNIVERSITY   (United Kingdom)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Arsenic trioxide; Caspase 3; Cell cycle arrest; Flow cytometry; Human papillomavirus E6; p53

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ARSENIC TRIOXIDE; CASPASE 3; PROTEIN E6; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL POPULATION; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; UPREGULATION; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CASPASE 3; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HELA CELLS; HUMANS; ONCOGENE PROTEINS, VIRAL; OXIDES; PAPILLOMAVIRUS INFECTIONS; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 84862796395     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834f1fd3     Document Type: Article

References (42)

1. Franco EL, Schlecht NF, Saslow D. The epidemiology of cervical cancer. Cancer J 2003; 9:348-359. (Pubitemid 44403488)
2. Sutcliffe S, Viscidi RP, Till C, Goodman PJ, Hoque AM, Hsing AW, et al. Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 2010; 19:614-618.
3. Neufcoeur PE, Arafa M, Delvenne P, Saussez S. Involvement of human papillomavirus in upper aero-digestive tracts cancers. Bull Cancer 2009; 96:941-950.
4. Shukla S, Bharti AC, Mahata S, Hussain S, Kumar R, Hedau S, et al. Infection of human papillomaviruses in cancers of different human organ sites. Indian J Med Res 2009; 130:222-233.
5. Zheng ZM, Baker CC. Paillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci 2006; 11:2286-2302. (Pubitemid 43822560)
6. Bharti A, Shukla S, Mahata S, Hedau S, Das BC. Anti-human papillomavirus therapeutics: facts and future. Indian J Med Res 2009; 130:296-310.
7. Huff J, Chan P, Nyska A. Is the human carcinogen arsenic carcinogenic to laboratory animals? Toxicol Sci 2000; 55:17-23. (Pubitemid 30252431)
8. Kwong YL, Todd D. Delicious poison: arsenic trioxide for the treatment of leukemia. Blood 1997; 89:3487-3488.
9. Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ, Chen Z. Arsenic trioxide, a therapeutic agent for APL. Oncogene 2001; 20:7146 -7153.
10. Zheng J, Deng YP, Lin C, Fu M, Xiao PG, Wu M. Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression. Int J Cancer 1999; 82: 286-292. (Pubitemid 29293790)
11. 3) on human breast cancer cells. J Cell Biochem 2004; 9:173-187.
12. Li X, Ding X, Adrian TE. Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells. Cancer Invest 2004; 22:389-400. (Pubitemid 39310909)
13. 3)-induced apoptosis in human glioblastoma cells. Cancer Sci 2005; 96:825-833.
14. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-19. (Pubitemid 29406813)
15. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC,Wacholder S. Human papillomavirus and cervical cancer. The Lancet 2007; 370:890-907. (Pubitemid 47371147)
16. Phelps WC, Yee CL, Munger K, Howley PM. The human papillomavirus type 16 E7 gene encodes transactivation and transforming functions similar to adenovirus E1A. Cell 1988; 58:539-547.
17. Spitkovsky D, Aengeneyndt F, Braspenning J, von Knebel Doeberitz M. p53- independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene. Oncogene 1996; 13:1027-1035. (Pubitemid 26329089)
18. Crook T, Tidy JA, Vousden KH. Degradation of p53 can be targeted by HPV 16 sequences distinct from those required for p53 binding and transactivation. Cell 1991; 67:547-556. (Pubitemid 121001469)
19. Huibregtse JM, Scheggner M, Howlet PM. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 1991; 10:4129-4135. (Pubitemid 21905444)
20. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63:1129-1135.
21. Storey A, Pim D, Murray A, Osborn K, Banks L, Crawford L. Comparison of the in vitro transforming activities of human papillomavirus types. EMBO J 1988; 7:1815-1820.
22. Werness BA, Levine AJ, Howley PM. Association of human papilomavirus type16 and 18 E6 protein with p53. Science 1990; 248:76-79.
23. Howie HL, Katzenellenbogen RA, Galloway DA. Papillomavirus E6 proteins. Virology 2009; 384:324-334.
24. Androphy EJ, Hubbert NL, Schiller JT, Lowy DR. Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. EMBO J 1987; 6:989-992.
25. Barbosa MS, Schlegel R. The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. Oncogene 1989; 4:1529-1532. (Pubitemid 20008936)
26. Bogaards JA, Coupé VM, Xiridou M, Meijer CJ,Wallinga J, Berkhof J. Longterm impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology 2011; 22:505-515.
27. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011; 22: 2675-2686.
28. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PMLRAR alpha/PML proteins. Blood 1996; 88:1052-1061.
29. Jiang XH, Wong BCY, Yuen ST, Jiang SH, Cho CH, Lai KC, et al. Arsenic trioxide induces apoptosis in human gastric cancer cells through upregulation of P53 and activation of caspase-3. Int J Cancer 2001; 91:173-179. (Pubitemid 32041736)
30. Walker AM, Stevens JJ, Ndebele K, Tchounwou PB. Arsenic trioxide modulates DNA synthesis and apoptosis in lung carcinoma cells. Int J Environ Res Public Health 2010; 7:1996-2007.
31. Chen MJ, Yang PY, Ye YZ, Hu DN, Chen MF. Arsenic trioxide induces apoptosis in uveal melanoma cells through the mitochondrial pathway. Am J Chin Med 2010; 38:1131-1142.
32. Li HM, Long Y, Qing C, Yu M, Li ZH, Zhang XM, et al. Arsenic trioxide induces apoptosis of Burkitt lymphoma cell lines through multiple apoptotic pathways and triggers antiangiogenesis. Oncol Res 2011; 19:149-163.
33. Woo SH, Park MJ, An S, Lee HC, Jin HO, Lee SJ, et al. Diarsenic and tetraarsenic oxide inhibit cell cycle progression and bFGF- and VEGF-induced proliferation of human endothelial cells. J Cell Biochem 2005; 95:120-130. (Pubitemid 41420222)
34. Meng R, Zhou J, Sui M, Li Z, Feng G, Yang B. Arsenic trioxide promotes mitochondrial DNA mutation and cell apoptosis in primary APL cells and NB4 cell line. Sci China Life Sci 2010; 53:87-93.
35. Um SJ, Lee SY, Lim EJ, Myoung J, Namkoong SE, Park JS. Down-regulation of human papillomavirus E6/E7 oncogene by arsenic trioxide in cervical carcinoma cells. Cancer Let 2002; 181:11-22. (Pubitemid 34310657)
36. Li X, Ding X, Adrian TE. Arsenic trioxide inhibits proliferation and induces apoptosis in pancreatic cancer cells. Anticancer Res 2002; 22:2205-2213. (Pubitemid 34857044)
37. Nakagawa Y, Akao Y, Morikawa H, Hirata I, Katsu K, Naoe T, et al. Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci 2002; 70:2253-2269. (Pubitemid 34251296)
38. Shen Zx, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89:3354-3360.
39. Soignet SL, Maslek P,Wang ZG, Jhanwar S, Calleja E, Dardashiti LJ, et al. Complete remission after treatment of acute promyelocystic leukemia with arsenic trioxide. N Engl J Med 1998; 339:1341-1348. (Pubitemid 28509343)
40. Dai J,Weinberg RS,Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93:268-277. (Pubitemid 29019412)
41. Howley PM, Scheffner M, Huibregtse J, Minger K. Oncoproteins encoded by the cancer-associated human papillomavirus target the products of the retinoblastoma and p53 tumor suppressor genes. Cold Spring Harbor Symp. Quant Biol 1991; 56:149-155.
42. Thomas M, Matlashewski G, Pim D, Banks L. Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation. Oncogene 1996; 123:265-273. (Pubitemid 26334858)